Wechselwirkungen · Rasilez
Rasilez 150 mg film-coated tablets Rasilez 300 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 7
HOS-208765 · Präparat HOS-154177
CYP450 interactions Aliskiren does not inhibit the CYP450 isoenzymes (CYP1A2, 2C8, 2C9, 2C19, 2D6, 2E1 and 3A). Aliskiren does not induce CYP3A4. Therefore, aliskiren is not expected to affect the systemic exposure of substances that inhibit, induce or are metabolised by these enzymes. Aliskiren is metabolised minimally by the cytochrome P450 enzymes. Hence, interactions due to inhibition or induction of CYP450 isoenzymes are not expected. However, CYP3A4 inhibitors often also affect P-gp. Increased aliskiren exposure during co-administration of CYP3A4 inhibitors that also inhibit P-gp can therefore be expected (see other P-gp references in section 4.5).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-10-02T02:00:00Z · SHA-256 4518ee1f6936dd9da7c06dbb3fa8bed38b206400f5cb767391af486f27614e43 · Passage 5224fdb679c3649a3d1087da789463ac735417aa5a945a51969fa1884e012393 · Zeichen 8271–8933 im Abschnitt